<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952196</url>
  </required_header>
  <id_info>
    <org_study_id>16.181</org_study_id>
    <nct_id>NCT02952196</nct_id>
  </id_info>
  <brief_title>Cannabioids as a New Intervention for Amphetamine Dependence</brief_title>
  <official_title>Cannabinoids as a New Intervention for Amphetamine Dependence: A Proof-of-concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Addiction to amphetamine is characterized by alternating phases of intoxication and short
      abstinence, followed by recurrent drug-craving episodes which result in distress and relapse.
      Addiction involves a number of neurotransmission systems, including the endocannabinoid
      system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic
      and neuroprotective properties. It has been shown to have multiple therapeutic properties for
      treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be
      potentially helpful in treating addiction, due to their effects on various neuronal circuits
      involved in this disorder.

      The investigators overall hypothesis is that cannabinoids are an interesting pharmacological
      contender to decrease amphetamine craving and treat amphetamine addiction.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    waiting for funding
  </why_stopped>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessing amphetamine craving</measure>
    <time_frame>everyday during the study (that will last 3 days for each participants)</time_frame>
    <description>using questionnaire to assess craving and taking vital signs</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Amphetamine Addiction</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cannabinoid dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cannabinoid dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drug administration</intervention_name>
    <description>administering drug to patient with amphetamine addiction</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>cannabinoid dose 1</arm_group_label>
    <arm_group_label>cannabinoid dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current DSM-V criteria for amphetamine use disorder

          -  Ability to give valid, informed consent

        Exclusion Criteria:

          -  Severe and/or unstable hepatic, neurologic (including diagnosis of seizures), cardiac
             (including arrhythmias) or renal disease, or any other severe or unstable medical
             condition that precludes safe participation in the study according to the study
             physician.

          -  Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or
             bipolar disorder; current acute psychosis, mania or severe suicidality

          -  Any serious medical condition or psychiatric illness that precludes the subject from
             signing the informed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</investigator_affiliation>
    <investigator_full_name>Didier Jutras-Aswad</investigator_full_name>
    <investigator_title>M.D., M.Sc., FRCPC</investigator_title>
  </responsible_party>
  <keyword>Amphetamine</keyword>
  <keyword>Cannabinoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

